Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis

Journal of Surgical Oncology

Volumn 99, Issue 7, 2009, Pages 409-413

  Vallbohmer D ^a   Drebber, U ^b   Schneider, P M ^a,c   Baldus, S ^c   Bollschweiler, E ^a   Brabender, J ^a   Warnecke Eberz, U ^a   Monig S ^a   Holscher A H ^a   Metzger, R ^a,d  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Gastric cancer; Neoadjuvant therapy; Prognosis; Response prediction; Survivin

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; SURVIVIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; GASTRECTOMY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOADJUVANT THERAPY; STOMACH NEOPLASMS;

EID: 66349092838     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21271     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Levi F, Lucchini F, Gonzalez JR, et al.: Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 2004;15:338-345. (Pubitemid 38262637)
3. De Vita F, Giuliani F, Galizia G, et al.: Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol 2007;18:120-123.
4. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
5. Ott K, Sendler A, Becker K, et al.: Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: A prospective phase II study. Gastric Cancer 2003;6:159-167. (Pubitemid 37221566)
6. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921. (Pubitemid 27353455)
7. Altieri DC: Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-8589. (Pubitemid 38019195)
8. Wang TT, Qian XP, Liu BR: Survivin: Potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol 2007;13:2784-2790. (Pubitemid 47008845)
9. Lehner R, Lucia MS, Jarboe EA, et al.: Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol 2002;10:134-138. (Pubitemid 34553169)
10. Kennedy SM, O'Driscoll L, Purcell R, et al.: Prognostic importance of survivin in breast cancer. Br J Cancer 2003;88:1077-1083. (Pubitemid 36560779)
11. Warnecke-Eberz U, Hokita S, Xi H, et al.: Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005;13:1241-1246.
12. Okada E, Murai Y, Matsui K, et al.: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001;163:109-116. (Pubitemid 32121836)
13. Trieb K, Lehner R, Stulnig T, et al.: Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003;29:379-382. (Pubitemid 36675696)
14. Schneider PM, Baldus SE, Metzger R, et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: Implications for response classification. Ann Surg 2005;242:684-692. (Pubitemid 41567124)
15. Li F, Ambrosini G, Chu EY, et al.: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;496:580-584. (Pubitemid 28563719)
16. Lu C, Altieri DC, Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998;58:1808-1812. (Pubitemid 28217451)
17. Yu J, Leung WK, Ebert MP, et al.: Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer 2002;87:91-97.
18. Lee GH, Joo YE, Koh YS, et al.: Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur J Gastroenterol Hepatol 2006;18:957-963. (Pubitemid 44213038)
19. Meng H, Lu CD, Dai DJ, et al.: Elevated expression level of wild-type survivin in gastric cancer promotes in vitro docetaxel-resistance. Zhonghua Yixue Zazhi 2004;84:2060-2063.
20. Yao XQ, Liu FK, Qi XP, et al.: Expression of survivin in human gastric adenocarcinomas: Correlation with proliferation and apoptosis. Zhonghua Waike Zazhi 2004;42:145-148.
21. Freier K, Pungs S, Sticht C, et al.: High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. Int J Cancer 2007;120:942-946. (Pubitemid 46175418)
22. Sarela AI, Macadam RC, Farmery SM, et al.: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000;46:645-650. (Pubitemid 30305781)
23. Tanaka K, Iwamoto S, Gon G, et al.: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-134. (Pubitemid 30064984)
24. Ponnelle T, Chapusot C, Martin L, et al.: Cellular localisation of survivin: Impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 2005;131:504-510. (Pubitemid 41215305)
25. Beardsmore DM, Verbeke CS, Davies CL, et al.: Apoptotic and proliferative indexes in esophageal cancer: Predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg 2003;7:77-86.